We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Pink Sheet is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Public offering nets a huge $352mm for Onyx Pharmaceuticals
31 Jan 2013
Executive Summary
Cancer therapeutics company Onyx Pharmaceuticals Inc. netted $352.4mm through the public sale of 4.4mm common shares at $81.50 apiece. The offering is the largest ever for the company, following a $311mm combined stock and debt sale in 2009. Onyx will use some of the proceeds to fund continuing development for its carfilzomib (Phase III for multiple myeloma) and oprozomib (Phase Ib/II for hematologic malignancies), and it will also put proceeds towards global commercialization activities for Krypolis injection, a carfilzomib formulation that received accelerated approval by the FDA in July 2012 for multiple myeloma patients who have already been treated with two other therapies (including bortezomib and an immunomodulatory agent), and are showing signs of disease progression.
Deal Industry
Biotechnology
Pharmaceuticals
Deal Status
Final
Deal Type
Financing
FOPO
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?